Navigation Links
Kips Bay Medical Announces Closing of its $16.5 Million Initial Public Offering of Common Stock
Date:2/16/2011

MINNEAPOLIS, Feb. 16, 2011 /PRNewswire/ -- Kips Bay Medical, Inc. ("Kips Bay"), a development stage medical device company focused on developing, manufacturing and commercializing external saphenous vein support technology, or eSVS MESH, for use in coronary artery bypass grafting, or CABG, today announced that it has closed its previously announced offering of 2,062,500 shares of its common stock at a price of $8.00 per share.  

Kips Bay received aggregate net proceeds of approximately $13.6 million after deducting underwriting discounts and commissions and offering expenses payable by Kips Bay. Kips Bay expects to use the net proceeds of this offering to seek regulatory approval to market eSVS MESH in the United States and abroad, including human clinical trials in the United States; develop and test additional applications of eSVS MESH; make certain milestone payments for acquired intellectual property; and for working capital and general corporate purposes.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as sole book-running manager for the offering, and Newbridge Securities Corporation, Caris & Company and Chardan Capital Markets, LLC acted as co-managers.

A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration. Copies of the final prospectus relating to the offering, when available, may be obtained for free by visiting the U.S. Securities and Exchange Commission website at http://www.sec.gov. Alternatively, a copy of the prospe
'/>"/>

SOURCE Kips Bay Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... England Journal of Medicine ( NEJM ) published ... oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients ... suggested ibrutinib may be effective and generally well-tolerated in ... a separate study examining the safety and efficacy of ...
(Date:6/19/2013)... 2013  Haemonetics Corporation (NYSE: HAE ... pursuit of its previously announced manufacturing transformation.  ... , Haemonetics has selected Sanmina Corporation (NASDAQ: ... of medical devices currently manufactured in ... provider of integrated manufacturing solutions, components, products and ...
(Date:6/19/2013)... YORK , June 19, 2013 /PRNewswire-iReach/ -- ... pioneer of modern hair transplant procedures and founder ... was included in the ,Best Doctors, issue of ... (Photo:  http://photos.prnewswire.com/prnh/20130619/CG34629 ) ... Best Doctors issue, and his reputation as world-renowned ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
... AstraZeneca (NYSE:,AZN) today announced that the U.S. Food ... (quetiapine fumarate) Extended-Release,Tablets for maintenance treatment of schizophrenia ... approved SEROQUEL XR for the acute treatment of,schizophrenia ... rates of symptom relapse, and as,a result, there ...
... from Fort Point Channel to the Cyclorama mark 16th Annual,24-hour ... thousands of youth to process with black and copper buckets ... The Boston Center,for the Arts as part of the annual ... event was named Best Project in a Public Space by ...
Cached Medicine Technology:SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 2SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 3SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 4SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 5SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 6SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 7SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia 8Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day 2Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day 3Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day 4
(Date:6/19/2013)... medicine and trauma surgery have had a significant ... immediately after major injuries, including burns. Patients ... now are at greatest risk from infections ... sepsis or from inflammation-induced multiorgan failure. ... (MGH) investigators that measures the movement of key ...
(Date:6/19/2013)... (June 19, 2013) In what is believed to ... most common form of hereditary dystonia a movement ... in deep brain stimulation report good success rates and ... the Movement Disorders Program at Cedars-Sinai Medical Center,s Department ... the Division of Neurosurgery at Beth Israel Deaconess Medical ...
(Date:6/19/2013)... The results of three important studies have been published ... journal of the Congress of Neurological Surgeons . ... & Wilkins , a part of Wolters Kluwer ... learning" using artificial neural networks (ANNs) may improve the ... cancers. Another study in the June Neurosurgery ...
(Date:6/19/2013)... Ann Arbor, Mich. Children had half as ... had evening office hours on five or more days ... experts at C.S. Mott Children,s Hospital and Johns Hopkins ... month in The Journal of Pediatrics and ... , "These findings are an important step in understanding ...
(Date:6/19/2013)... is available in Spanish . ... neglected diseases, it goes by the name of the 10/90 ... devoted to conditions that accounted for 90 per cent of ... that the Drugs for Neglected Diseases initiative (DNDi) came into ... organization has been granted the BBVA Foundation Frontiers of Knowledge ...
Breaking Medicine News(10 mins):Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5
... as a key resource for finding the best Government and nonprofit ... straightforward and credible information catalogued on the site. But it is ... for disease prevention and wellness information interactive and action oriented. ... ...
... Amoena, the worldwide leader of post-breast surgery ... Hannah Collection, the industry,s first post-surgical garments ... ease discomfort after breast surgery.(Logo: ... http://www.newscom.com/cgi-bin/prnh/20090408/CL96087 )The post-surgical camisole ...
... ORTHOCON¿ Inc. today announced that Paul R. Sohmer, ... Executive Officer. The company also announced the closing of ... healthcare investors. ORTHOCON is developing innovative implantable devices ... platform may be leveraged to deliver a variety of ...
... high marks on intentions for good nutrition but lack ... no surprise that with the current economic conditions, three-quarters ... healthy eating is largely dependent on what food families ... family pantries, fridges, and freezers, Rutgers University ...
... 8 Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) ... BG Medicine (BGM) in its Phase 2 clinical safety ... this collaboration, BGM will measure levels of Galectin-3 in ... for cardiac remodeling associated with advanced stages of heart ...
... April 8 The College of American Pathologists (CAP), ... and deeming authority under the Clinical Laboratory Improvement Amendments ... Services (CMS) since 1995, has been notified that it ... a six-year period, the longest period available for this ...
Cached Medicine News:Health News:healthfinder.gov Adds New Interactive Features to Its Web Site 2Health News:Amoena Introduces First Post Surgical Garments With Vitamin E & Aloe to Help Soothe and Comfort After Breast Surgery 2Health News:ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 2Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 4Health News:CAP Deeming Status Renewed 2
... borescopes are rigid endoscopes for general applications and ... The diameters of borescopes, i.e. rigid endoscopes, range ... directions from 0 up to a 120 retrospection, ... and wide angle view. Endoscopes with working lengths ...
Long system ventriculoscope for stereotactic frames....
... absorbable implant for the bridging of Dura Mater ... pliable, regardless of being used dry or wet. ... be taken, while implanting, to ensure that the ... oriented towards the cortex or the spinal cord ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Medicine Products: